Takeda Pharmaceutical Company (4502) investor relations material

Executive summary

• Q1 FY2026 results delivered a solid start, with revenue at JPY 1,219.9 billion (+10.2% actual, flat at CER), core operating profit at JPY 358.9 billion (+11.5% actual, flat at CER), and performance in line with expectations.

• Net profit declined 8.9% to JPY 113.2 billion, mainly due to higher tax expenses and restructuring costs.

• Progress continued on transformation initiatives and late-stage pipeline advancement, with launch preparations for ORZEYFUL, rusfertide, and zasocitinib on track.

• Growth in core in-line brands and new launches largely offset declines from mature portfolio and loss of exclusivity.

• Transformation program savings are funding investments in new launches and R&D.

Financial highlights

• Gross margin improved to 66.7% from 65.2% YoY, benefiting from FX and a one-time divestiture milestone.

• Core EPS was JPY 154 (up 1.5% actual, down 11.8% at CER); reported EPS was JPY 72.

• Adjusted free cash flow dropped 63.9% to JPY 68.6 billion, mainly due to higher working capital needs and a $200M payment to Protagonist.

• Adjusted net debt/adjusted EBITDA ratio was 2.7x at quarter-end.

• Free cash flow guidance for FY2026 remains JPY 650–750 billion.

Outlook and guidance

• FY2026 revenue forecast is JPY 4,640.0 billion (+3.0% YoY); core operating profit forecast JPY 1,160.0 billion (-1.1% YoY); core EPS JPY 472 (-8.7% YoY).

• At CER, management guides for a low-single-digit decline in core revenue, 5–8% decline in core operating profit, and mid-teens decline in core EPS.

• Annual dividend forecast raised to JPY 204 per share.

• Full-year guidance reaffirmed, with focus on deleveraging and capital efficiency.

• Guidance reflects investment in new launches and R&D, with mature portfolio headwinds.